Name | HBV-IN-20 |
---|
Description | HBV-IN-20 is a potent and oral active HBV inhibitor with an EC50 of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators)[1]. |
---|---|
Related Catalog | |
Target |
EC50: 0.46 µM (HBV)[1] |
In Vitro | HBV-IN-20 (compound 61) (5 µM; 6 days) is a typical type II CpAM (core protein assembly modula tors)[1]. Western Blot Analysis[1] Cell Line: HepDES19 cells Concentration: 5 µM Incubation Time: Result: Was a typical type II CpAM (core protein assembly modula tors). |
In Vivo | HBV-IN-20 (3 mg/kg for i.v.; 10 mg/kg for p.o.) shows 69% of oral bioavailability[1]. Pharmacokinetic Parameters of HBV-IN-20 in mouse[1]. Compd Admin. Cl-obs (mL/min/kg) T1/2 (hr) AUClast (h*ng/mL) Vss-obs (L/kg) Cmax (ng/mL) F (%) 61 i.v. 25.5 0.6 1952 0.8 p.o. 0.7 4516 2727 69Mouse; 3 mg/kg for i.v.; 10 mg/kg for p.o. Animal Model: Mouse[1] Dosage: Administration: 3 mg/kg for i.v.; 10 mg/kg for p.o. Result: Showed 69% of oral bioavailability. |
References |
Molecular Formula | C16H18ClFN2O2 |
---|---|
Molecular Weight | 324.78 |